Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.83 |
| ▸ | KDR | P35968 | 4/20 | 0.83 |
| ▸ | FBP1 | P09467 | 2/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.83 |
| ▸ | AURKA | O14965 | 1/20 | 0.83 |
| ▸ | INSR | P06213 | 1/20 | 0.83 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.83 |
| ▸ | FLT4 | P35916 | 1/20 | 0.83 |
| ▸ | CLK1 | P49759 | 1/20 | 0.83 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.83 |
| ▸ | TEK | Q02763 | 1/20 | 0.83 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.83 |
| ▸ | RAF1 | P04049 | 1/20 | 0.76 |
| ▸ | BRAF | P15056 | 1/20 | 0.76 |
| ▸ | RET | P07949 | 2/20 | 0.72 |
| ▸ | KIF5B | P33176 | 2/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.72 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.68 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679736 | 1.00 | EGFR (0.83) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL30124192 | 1.00 | EGFR (0.83) | EGFRKDRFBP1ERBB2AURKA | |
| Hydrochloric Acid SCHEMBL28040041 | 0.99 | EGFR (0.81) | EGFRKDRFBP1ERBB2AURKA | |
| Hydrochloric Acid SCHEMBL27915151 | 0.98 | EGFR (0.80) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL3238800 | 0.96 | EGFR (0.83) | EGFRKDRFBP1ERBB2AURKA | |
| Acetic Acid SCHEMBL29234690 | 0.95 | EGFR (0.75) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL13006609 | 0.93 | EGFR (0.71) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL14515606 | 0.91 | KDR (0.72) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL2099106 | 0.91 | EGFR (1.00) | EGFRKDRFBP1ERBB2AURKA | |
| SCHEMBL30505605 | 0.91 | EGFR (1.00) | EGFRKDRFBP1ERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063399-A | Method for synthesizing N- (3-chloro-4-fluorophenyl) -6-hydroxy-7-methoxy-4-quinazolinamine | 杭州微流汇科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| EP-2155656-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | Cipla Limited (IN) | 2010-02-24 | — | — | EP | claimed |
| WO-2008125867-A2 | PROCESS FOR THE PREPARATION OF GEFITINIB | CIPLA LIMITED (IN) | 2008-10-23 | — | — | WO | claimed |
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-03 | — | — | US | disclosed |
| US-20250236596-A1 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | UNIV GEORGIA (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4587017-A2 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | University of Georgia Research Foundation, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118063399-A | Method for synthesizing N- (3-chloro-4-fluorophenyl) -6-hydroxy-7-methoxy-4-quinazolinamine | 杭州微流汇科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118063399-A | Method for synthesizing N- (3-chloro-4-fluorophenyl) -6-hydroxy-7-methoxy-4-quinazolinamine | 杭州微流汇科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-5866572-A | RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0892799-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1999-01-27 | — | — | EP | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| US-5770603-A | ANTICARCINOGENIC AGENTS | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | disclosed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| WO-1997038994-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-10-23 | — | — | WO | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | EGFR 1/4885KDR 212/4885FBP1 3679/4885 |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885KDR 241/4885FBP1 2591/4885 |
| US-20250236596-A1 | HYDROXYLAMINE-BASED EGFR INHIBITORS FOR TREATMENT OF CANCER WITH BRAIN METASTASES | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDR 16/4885FBP1 4323/4885 |
| US-12564638-B2 | EGFR protein degradant and anti-tumor application thereof | EGFR, ERBB2, ERBB3 | EGFR 1/4885KDR 35/4885FBP1 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.